title: The design of an observational study of hypertension management, adherence and pressure control in Blood Pressure Success Zone Program participants.
abstract: OBJECTIVE
  The Blood Pressure Success Zone (BPSZ) Program, a nationwide initiative, provides education in addition to a complimentary trial of one of three antihypertensive medications. The BPSZ Longitudinal Observational Study of Success (BPSZ-BLISS) aims to evaluate blood pressure (BP) control, adherence, persistence and patient satisfaction in a representative subset of BPSZ Program participants. The BPSZ-BLISS study design is described here.
  
  
  METHODS
  A total of 20,000 physicians were invited to participate in the study. Using a call centre supported Interactive Voice Response System (IVRS), physicians report BP and other data at enrolment and every usual care visit up to 12 +/- 2 months; subjects self-report BPs, persistence, adherence and treatment satisfaction at 3, 6 and 12 months post-BPSZ Program enrolment. In addition to BPSZ Program enrolment medications, physicians prescribe antihypertensive medications and schedule visits as per usual care. The General Electric Healthcare database will be used as an external reference.
  
  
  RESULTS
  After 18 months, over 700 IRB approved physicians consented and enrolled 10,067 eligible subjects (48% male; mean age 56 years; 27% newly diagnosed); 97% of physicians and 78% of subjects successfully entered IVRS enrolment data. Automated IVRS validations have maintained data quality (< 5% error on key variables). Enrolment was closed 30 April 2007; study completion is scheduled for June 2008.
  
  
  CONCLUSIONS
  The evaluation of large-scale health education programmes requires innovative methodologies and data management and quality control processes. The BPSZ-BLISS design can provide insights into the conceptualisation and planning of similar studies.
authors.affiliation: United BioSource Corporation, Health Care Analytics, Montreal, QC, Canada. krista.payne@unitedbiosource.com
authors.forename: K A
authors.initials: KA
authors.lastname: Payne
authors.forename: J J
authors.initials: JJ
authors.lastname: Caro
authors.forename: W L
authors.initials: WL
authors.lastname: Daley
authors.forename: Z M
authors.initials: ZM
authors.lastname: Khan
authors.forename: K J
authors.initials: KJ
authors.lastname: Ishak
authors.forename: K
authors.initials: K
authors.lastname: Stark
authors.forename: D
authors.initials: D
authors.lastname: Purkayastha
authors.forename: J
authors.initials: J
authors.lastname: Flack
authors.forename: E
authors.initials: E
authors.lastname: Velázquez
authors.forename: S
authors.initials: S
authors.lastname: Nesbitt
authors.forename: D
authors.initials: D
authors.lastname: Morisky
authors.forename: R
authors.initials: R
authors.lastname: Califf
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data; D010353:Patient Education as Topic; D017060:Patient Satisfaction; D012107:Research Design; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents